Artemether-lumefantrine treatment failure despite adequate lumefantrine day 7 concentration in a traveller with Plasmodium falciparum malaria after returning from Tanzania.
Artemether-lumefantrine is currently first-line therapy of Plasmodium falciparum malaria in many countries. This report describes a treatment failure despite adequate drug concentrations in a traveller returning from sub-Saharan Africa. Genotyping confirmed recrudescence and suggested reduced sensitivity. Potential sub-optimal effect of artemether-lumefantrine highlights the need to follow non-immune individuals the weeks after treatment.
Infectious Diseases Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. anna.farnert@ki.se
Anna
A
Färnert
Johan
J
Ursing
Thomas
T
Tolfvenstam
Josea
J
Rono
Lillemor
L
Karlsson
Elda
E
Sparrelid
Niklas
N
Lindegårdh
D000962:Antimalarials / Q000008:administration & dosage*; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins / Q000008:administration & dosage*; D004338:Drug Combinations; D004351:Drug Resistance; D004983:Ethanolamines / Q000008:administration & dosage*; D005449:Fluorenes / Q000008:administration & dosage*; D005838:Genotype; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010963:Plasmodium falciparum / Q000145:classification / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification; D012008:Recurrence; D013636:Tanzania; D014195:Travel; D017211:Treatment Failure
D000962:Antimalarials; D000077611:Artemether, Lumefantrine Drug Combination; D037621:Artemisinins; D004338:Drug Combinations; D004983:Ethanolamines; D005449:Fluorenes